Risk of Cardiovascular Disease in Patients With Classical Hodgkin Lymphoma: A Danish Nationwide Register-Based Cohort Study

• Published in: European journal of haematology 2024-11
• Main Authors: Godtfredsen, Sissel J, Yonis, Harman, Baech, Joachim, Al-Hussainy, Nour R, Riddersholm, Signe, Kober, Lars, Schou, Morten, Christensen, Jacob Haaber, Hutchings, Martin, Dahl-Sørensen, Rasmus Bo, Kamper, Peter, Dietrich, Caroline E, Andersen, Mikkel Porsborg, Torp-Pedersen, Christian, Sogaard, Peter, El-Galaly, Tarec Christoffer, Kragholm, Kristian H
• Format: Article
• Language: English
• ISSN: 0902-4441; 1600-0609; 1600-0609
• DOI: 10.1111/ejh.14334

Risk of cardiovascular disease (CVD) in patients with classical Hodgkin lymphoma (cHL) undergoing contemporary treatment is unclear. cHL patients ≥ 18 years at diagnosis treated with doxorubicin-containing chemotherapy between 2000 and 2022 were matched 1:5 with comparators on birth year, sex, and Charlson Comorbidity Index at time of matching (score of 0 or ≥ 1). Cause-specific cumulative incidence of a composite of CVDs with corresponding 95% confidence intervals (CIs) were computed with death and lymphoma relapse as competing events (i.e., by censoring individuals at such occurrences) using the Aalen-Johansen estimator. A total of 1905 patients and 9525 comparators with a median follow-up of 10 years (interquartile range, [IQR]: 5.9-17.4). Median age was 39 years (IQR: 27-56), median cumulative doxorubicin dose was 250 mg/m (IQR: 200-300). The CVD cumulative incidences were 4.7% (95% CI: 3.6-5.7) for patients versus 2.6% (95% CI: 2.3-2.9) for comparators at 5 years, 8.9% (95% CI: 7.2-10.5) versus 5.5% (95% CI: 4.9-6.0) at 10 years, and 17.0% (95% CI: 14.1-19.9) versus 8.2% (95% CI: 7.4-9.0) at 15 years. CVD remains a substantial effect after contemporary treatment for cHL, suggesting that awareness of symptoms and a low threshold for referral to diagnostic examination are still important measures during survivorship.